Familial hypercholesterolemia and vulnerability of coronary plaque in patients with coronary artery disease

Masahiro Katamine, Yoshiyasu Minami*, Takuya Hashimoto, Junya Ako

Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan

ARTICLE INFO

Keywords:
Low-density lipoprotein cholesterol
Optical coherence tomography
Vulnerable plaque

ABSTRACT

Objectives: Patients with familial hypercholesterolemia (FH) are at a very high risk of coronary artery diseases. The aim of the present study was to clarify the characteristics of coronary plaque in patients with FH.

Design and Methods: A total of 569 patients who underwent optical coherence tomography (OCT) imaging of culprit plaque were included. The characteristics of culprit plaque were compared between patients with and without FH.

Results: A total of 38 patients (6.7%) were clinically diagnosed with FH. The location of the culprit plaque was significantly different (p < 0.001) with a trend toward higher frequency of left main lesion in the FH group than in the group with no FH (7.9 vs. 0%). Culprit plaque was significantly shorter in patients with FH than those without FH (28.1 vs. 33.2 mm, p = 0.016). A trend toward higher prevalence of plaque with macrophage accumulation in patients with FH than those without FH (50.0 vs. 34.7%, p = 0.056) was observed, although the prevalence of other vulnerable characteristics including thin-cap fibroatheroma (TCFA) was comparable between patients with and without FH. Among patients with FH, significant increases in the prevalence of lipid-rich plaque (p = 0.028) and TCFA (p = 0.003) were observed according to the increase in low-density lipoprotein cholesterol (LDL-C) levels.

Conclusions: Patients with FH had shorter culprit plaque without significant difference in the prevalence of vulnerable plaque components compared with patients without FH. A higher LDL-C level was associated with higher prevalence of vulnerable plaque in patients with FH.

1. Introduction

Patients with familial hypercholesterolemia (FH) are at a very high risk of coronary artery diseases. Because they are exposed to high LDL cholesterol (LDL-C) levels from birth [1], the onset of acute coronary syndrome in patients with FH is at a younger age than in patients without FH [2]. These distinct characteristics may cause the difference in the characteristics of coronary atherosclerosis between patients with and without FH. Previous studies using coronary angiography and coronary computed tomography have reported more multivessel disease and left main disease in patients with FH than those without FH [3,4]. In addition, several reports using intra-coronary imaging have suggested the larger number of high-risk plaques in patients with FH [5,6]. However, the detailed characteristics of coronary plaque in patients with FH remain unclear. The purpose of our present study was to clarify the morphological

* Corresponding author. Department of Cardiovascular Medicine, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0374, Japan.

E-mail address: arg12391@yahoo.co.jp (Y. Minami).

https://doi.org/10.1016/j.plabm.2021.e00202

Received 29 June 2020; Accepted 13 January 2021

© 2021 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
characteristics of coronary plaque in patients with FH using optical coherence tomography (OCT), which has the highest spatial resolution among clinically available intra-coronary imaging modalities.

2. Methods

2.1. Study population

A total of 1137 consecutive patients underwent percutaneous coronary intervention (PCI) at our institution between June 2016 and March 2019. Among them, we identified 672 consecutive patients who underwent OCT assessment of culprit lesions before stenting. Of those, a total of 569 patients were enrolled in the present study after excluding cases of restenosis (n = 84) and poor OCT images (n = 19; Fig. 1). The study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the ethics committees of our institution.

2.2. Definitions

FH was diagnosed using the 2017 Japan Atherosclerosis Society guidelines [2] (Fig. 2). The LDL-C levels before the prescription of lipid-lowering drugs were collected from the hospital record to diagnose FH. If the LDL-C levels before treatment were not available, we used serum LDL-C levels obtained from the patients 1 day before PCI. Achilles tendon thickness was measured on soft x-ray radiogram according to a recommended method (Supplementary Fig. 1) [7]. According to a report demonstrating a 1-mm gap between local measurement by institutional investigators and central measurement by experts [8], we defined Achilles tendon thickening as the adjusted Achilles tendon thickness of 9 mm or more, which was calculated by the measured Achilles tendon thickness minus 1 mm. A family history was defined as positive for FH and/or premature CAD (<55 years in men and <65 years in women) within first- and second-degree relatives [2]. Acute coronary syndrome (ACS) consisted of ST-segment elevation myocardial infarction and non-ST-segment elevation ACS. Other cases were categorized as stable coronary disease. Dyslipidemia was defined as LDL-C levels over 140 mg/dL and/or the prescription of lipid-lowering drugs. Multivessel disease was defined as 70% or greater stenosis and/or PCI history in at least one other epicardial coronary artery in addition to the culprit artery.

2.3. Optical coherence tomography image acquisition and analysis

OCT images of culprit lesions were acquired before stent implantation after 100–200 μg i.c. nitroglycerin using frequency-domain OCT (ILUMIEN OCT Intravascular Imaging Systems; Abbott, Santa Clara, CA, USA) (Fig. 3). All the images were analyzed using offline proprietary software at the cardiovascular laboratory at the Kitasato University School of Medicine. The images were qualitatively and quantitatively analyzed at 0.2-mm intervals. Plaque morphologies were assessed using previously established criteria [9,10]. Fibrous cap thickness was measured at its thinnest part on three times, and the average was calculated. Thin-cap fibroatheroma (TCFA) was defined as a plaque with a lipid arc >90° and the thickness of the fibrous cap <65 μm. Bright spots within the fibrous cap with backward shadowing were considered as macrophage accumulation [10]. Microchannels were defined as black holes or tubular structures of 50–100 μm in diameter, which were present within a plaque on at least 3 consecutive cross-sectional frames [11]. Cholesterol crystals were defined as linear and thin regions with high light intensity without signal attenuation [12]. Calcifications were defined as heterogeneous or signal-poor areas delimited by sharp borders. Spotty calcification was defined as calcification with an arc <90° [13].

Fig. 1. Study flow chart
FH, familial hypercholesterolemia; OCT, optical coherence tomography; PCI, percutaneous coronary intervention.
Large calcification was defined as calcification with an arc ≥180° [14]. Thrombus was defined as a mass >250 μm protruding from the luminal surface or floating within the lumen [9,15].

2.4. Statistical analysis

Continuous variables are expressed as mean ± standard deviation and compared using the unpaired t-test or the Wilcoxon rank-sum test. Categorical variables are presented as numbers and frequencies and compared using the Chi-square test. The Cochran–Armitage trend test and the Jonckheere-Terpstra trend test were used to examine the frequency of OCT findings of the culprit lesion according to the LDL-C levels and Achilles tendon thickness among patients with FH. A p value < 0.05 was considered statistically significant. Statistical analyses were performed using JMP version 13 software (SAS Institute, Cary, NC, USA) and SPSS version 24 software (IBM SPSS, Chicago, IL, USA).
3. Results

3.1. Baseline characteristics

A total of 38 patients (6.7%) were diagnosed with FH in the present cohort. Clinical characteristics according to the presence of FH are shown in Table 1 and Supplementary Table 1. The location of the culprit was significantly different (p < 0.001) with a trend toward higher frequency of the left main lesion in the FH group than in the group with no FH (7.9 vs. 0%). The left ventricular ejection fraction on echocardiogram was significantly lower in the FH group than in the group with no FH (52.2 ± 13.2 vs. 57.1 ± 12.4%, p = 0.028). Laboratory findings obtained from the patients 1 day before PCI are shown in Table 2 and Supplementary Table 1. The LDL-C levels (119.9 ± 45.9 vs. 97.0 ± 35.2, p = 0.003) were significantly higher in the FH group than in the group with no FH.

3.2. OCT findings of culprit plaque

The results of OCT analyses of culprit plaques are shown in Table 3. A trend toward higher prevalence of plaque with macrophage accumulation in the FH group than in the group with no FH (50.0 vs. 34.7%, p = 0.056) was observed. On the other hand, a trend toward lower prevalence of calcification in the FH group than in the group with no FH (71.1 vs. 82.1%, p = 0.091) was observed. The prevalence of other plaque characteristics including lipid-rich plaque, TCFA, microchannel, thrombus, and cholesterol crystal were comparable in the 2 groups. The lesion was significantly shorter in the FH group than in the group with no FH (28.1 vs. 33.2 mm, p = 0.016). The results according to clinical presentation are described in Supplementary Tables 2 and 3. Among patients with stable coronary disease, the prevalence of plaque with macrophage accumulation was significantly higher in the FH group than in the group with no FH (51.7 vs. 32.2%, p = 0.032).

3.3. OCT findings of culprit plaque according to the LDL-C levels among patients with FH

The characteristics of culprit plaque in patients with FH were compared among subgroups classified by tertiles of the LDL-C levels (Fig. 4 and Supplementary Table 4). The incremental frequency of lipid-rich plaque (p = 0.028) and TCFA (p = 0.003) according to the increase in LDL-C levels was observed. The results in patients with no FH are shown in Supplementary Fig. 2.

| Table 1 | Clinical characteristics. |
|---------|---------------------------|
| Variables | FH (+) n = 38 | FH (-) n = 531 | p value |
| Age, year | 66.1 ± 12.1 | 69.0 ± 10.5 | 0.213 |
| Male, n (%) | 32 (84.2) | 418 (78.7) | 0.421 |
| BMI, kg/m² | 24.8 ± 3.27 | 24.5 ± 8.56 | 0.233 |
| Culprit vessel, n (%) | | | <0.001 |
| LAD | 17 (44.7) | 306 (57.6) | |
| LCX | 6 (15.8) | 74 (13.9) | |
| RCA | 12 (31.6) | 149 (28.1) | |
| LM | 3 (7.9) | 2 (0) | |
| Acute coronary syndrome, n (%) | 9 (23.7) | 134 (25.2) | 0.831 |
| Multivessel disease, n (%) | 27 (71.1) | 307 (57.8) | 0.109 |
| Risk factors, n (%) | | | |
| Hypertension | 22 (57.9) | 383 (72.1) | 0.061 |
| Dyslipidemia | 28 (73.7) | 313 (58.9) | 0.073 |
| Diabetes mellitus | 19 (50.0) | 241 (45.4) | 0.581 |
| Current smoker | 8 (21.1) | 104 (19.6) | 0.880 |
| CKD (eGFR < 60) | 22 (57.9) | 261 (49.2) | 0.298 |
| MI history | 14 (36.8) | 148 (27.9) | 0.243 |
| PCI history | 21 (55.3) | 216 (40.7) | 0.082 |
| CABG history | 0 (0) | 11 (2.1) | 0.369 |
| Echo LVEF, % | 52.2 ± 13.2 | 57.1 ± 12.4 | 0.028 |
| Medication, n (%) | | | |
| ACE inhibitor/ARB | 29 (76.3) | 337 (63.5) | 0.113 |
| Beta blocker | 24 (63.2) | 247 (46.5) | 0.048 |
| Insulin | 3 (7.9) | 47 (8.9) | 0.835 |
| Statin | 32 (84.2) | 389 (73.3) | 0.142 |
| Ezetimibe | 10 (26.3) | 31 (5.8) | <0.001 |

ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BMI, body mass index; CABG, coronary artery bypass grafting; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; FH, familial hypercholesterolemia; LAD, left anterior descending artery; LCX, left circumflex artery; LM, left main artery; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; RCA, right coronary artery.
3.4. OCT findings of the culprit plaque according to Achilles tendon thickness among patients with FH

The characteristics of the culprit plaque in patients with FH were compared among subgroups classified by tertiles of maximum Achilles tendon thickness (Fig. 5 and Supplementary Table 5). No significant difference was observed in the frequency of plaque characteristics according to Achilles tendon thickness.

4. Discussion

The main findings of the present study are as follows: (1) Patients with FH had shorter culprit plaque than those without FH. (2) There was a trend toward higher prevalence of culprit plaque with macrophage accumulation in patients with FH than in those without FH. (3) A higher level of LDL-C was associated with higher prevalence of lipid-rich plaque and TCFA among patients with FH.

4.1. Focal plaque vulnerability of the culprit lesion in patients with FH

The characteristics of coronary plaque in patients with FH have been reported in several studies. Sugrue et al. investigated the angiographical characteristics of coronary atherosclerosis in patients with FH [4]. The authors found that patients with FH had a higher prevalence of left main disease than those without FH. Pang et al. also reported the higher prevalence of coronary plaque in the left coronary system including left main trunk in patients with genetically confirmed FH than age-matched controls in a study using cardiac computed tomography angiography [3]. These findings are consistent with our findings showing a difference in the location of the culprit lesion between patients with and without FH with a trend toward higher prevalence of the left main disease in patients with FH. Because the left main is short but usually widest among coronary arteries, patients with FH may be susceptible to focal large plaque rather than diffuse long plaque. In fact, we demonstrated that the culprit lesions were significantly shorter in patients with FH than those without FH. Because a trend toward lower prevalence of calcification in patients with FH than in those without FH was observed in the

| Table 2 |
| Laboratory findings. |
| Variables | FH (+) n = 38 | FH (-) n = 531 | p value |
| HbA1c, % | 6.62 ± 1.15 | 6.49 ± 1.12 | 0.378 |
| LDL-C, mg/dL | 119.2 ± 45.9 | 97.0 ± 35.2 | 0.003 |
| HDL-C, mg/dL | 53.6 ± 16.3 | 51.8 ± 15.8 | 0.478 |
| Triglyceride, mg/dL | 144.5 [99.0, 203.3] | 124 [85, 179] | 0.117 |
| Serum creatinine, mg/dL | 0.98 [0.82, 1.13] | 0.95 [0.8, 1.13] | 0.757 |
| eGFR, ml/min/1.73 m² | 56.0 [50.5, 69.3] | 59.0 [47.0, 70.0] | 0.925 |
| hs-CRP, mg/dL | 0.16 [0.05, 0.67] | 0.11 [0.05, 0.33] | 0.174 |
| BNP, pg/mL | 102.5 [50.8, 234.9] | 88.2 [31.2, 228.9] | 0.447 |

BNP, b-type natriuretic peptide; eGFR, estimated glomerular filtration rate; FH, familial hypercholesterolemia; HbA1c, glycosylated hemoglobin; HDL-C, high-density lipoprotein cholesterol; hs-CRP, high sensitivity C-reactive protein; LDL-C, low-density lipoprotein cholesterol.

| Table 3 |
| OCT findings of culprit lesion according to the presence of FH. |
| Variables | FH (+) n = 38 | FH (-) n = 531 | p value |
| Qualitative assessment, n (%) | | | |
| Lipid-rich plaque | 19 (50.0) | 208 (39.2) | 0.188 |
| TCFA | 7 (18.4) | 115 (21.7) | 0.639 |
| Macrophage | 19 (50.0) | 184 (34.7) | 0.056 |
| Microchannel | 10 (26.3) | 121 (22.8) | 0.622 |
| Calcification | 27 (71.1) | 436 (82.1) | 0.091 |
| Large calcification | 13 (34.2) | 247 (46.5) | 0.141 |
| Spotty calcification | 26 (68.4) | 421 (79.3) | 0.115 |
| Thrombus | 4 (10.5) | 69 (13.0) | 0.657 |
| Cholesterol crystal | 7 (18.4) | 95 (17.9) | 0.947 |
| Quantitative assessment | | | |
| Max arc, ° | 257.1 ± 75.1 | 281.4 ± 74.9 | 0.238 |
| Thinnest FCT, μm | 104.2 ± 61.1 | 85.3 ± 54.8 | 0.081 |
| Distal reference vessel area, mm² | 4.78 ± 2.53 | 4.82 ± 2.94 | 0.842 |
| Distal reference vessel diameter, mm | 2.38 ± 0.64 | 2.38 ± 0.67 | 0.818 |
| Proximal reference vessel area, mm² | 6.97 ± 2.66 | 7.07 ± 2.88 | 0.951 |
| Proximal reference vessel diameter, mm | 2.92 ± 0.56 | 2.93 ± 0.59 | 0.985 |
| Minimal lumen area, mm² | 1.43 ± 0.66 | 1.44 ± 0.73 | 0.904 |
| Minimal lumen diameter, mm | 1.31 ± 0.28 | 1.30 ± 0.30 | 0.820 |
| Percent area stenosis, % | 74.9 ± 7.12 | 74.1 ± 10.8 | 0.964 |
| Lesion length, mm | 28.1 ± 16.0 | 33.2 ± 14.0 | 0.016 |

FCT, fibrous cap thickness; FH, familial hypercholesterolemia; TCFA, thin cap fibroatheroma.
The present study, the majority of plaques might be focal lipid plaque rather than diffuse calcified plaque in patients with FH. Another important OCT finding in our study was a trend toward higher prevalence of plaque with macrophage accumulation in patients with FH than in those without FH. Among several plaque components, macrophage plays central roles for the deterioration of the integrity of the fibrous cap overlying the lipid core and subsequent incidence of acute coronary syndrome [16,17]. Although the significant difference in hsCRP levels between patients with and without FH was not demonstrated in the present study, the higher prevalence of plaque with macrophage accumulation may suggest the enhanced inflammatory cell infiltration at the culprit lesion in patients with FH. In fact, a recent report using OCT images demonstrated the presence of lipid-rich plaque along with macrophage accumulation in a left main lesion in patients with FH presenting as acute coronary syndrome [5]. Because a pre-clinical study demonstrated a significant correlation between the longer high-fat exposure and the larger plaque area with macrophage [18], the long duration of high LDL-C exposure in patients with FH might partly cause the trend toward higher prevalence of plaque with macrophage accumulation shown in the present study. Further studies targeting focal and systemic status of inflammation in patients with FH may explore other therapeutic options which could complement current pharmacological regimens for patients with FH.

4.2. Elevated LDL-C levels and vulnerability of culprit plaque in patients with FH

The impact of LDL-C levels on the incidence of cardiovascular events among patients with FH has been reported in several studies [19,20]. Silva et al. prospectively investigated the incidence of cardiovascular events for one year in patients with FH. The authors demonstrated that the baseline LDL-C level was 29% higher in patients with subsequent cardiovascular events than in those without cardiovascular events [19]. The reason for the higher incidence of cardiovascular events in patients with higher LDL-C levels can be explained by the advanced status of coronary artery disease. Neefjes et al. investigated the coronary plaques in cardiac asymptomatic patients with FH using computed tomography. The authors demonstrated the significant association between the treated LDL-C levels and the extent of coronary artery disease [21]. In the present study, we further showed the significant correlation between higher LDL-C levels and higher prevalence of lipid-rich plaque and TCFA at the culprit coronary lesion among patients with FH. Because the presence of TCFA has been demonstrated as the most critical morphological discriminator for plaque rupture among plaque characteristics, the present results suggested the presence of rupture-prone plaque in patients with FH concomitant with higher LDL-C levels [22]. In conjunction with the findings in the present study and previous studies, patients with FH and higher LDL-C levels should be considered at extremely high risk for cardiovascular events caused by vulnerable coronary plaque, although all patients with FH are at a higher risk for cardiovascular disease than those without FH. Studies incorporating life-long accumulated LDL-C levels in addition to the

![Fig. 4. OCT findings of culprit lesion according to LDL-C levels among patients with FH](image-url)

FH, familial hypercholesterolemia; LDL-C, low-density lipoprotein cholesterol; OCT, optical coherence tomography.
cross-sectional assessment of LDL-C may give further insight into the correlation between LDL-C and the development and deterioration of coronary plaques.

4.3. Limitations

Our study had several limitations. First, this was a retrospective study conducted in a single center. Patients with OCT imaging of culprit lesions were exclusively included in the present study, thus causing possible selection bias. We did not exclusively include patients at their first chance of revascularization. This might also cause selection bias. Second, we did not perform genetic molecular analysis to diagnose FH. Third, Achilles tendon thickness was evaluated only by radiography. Although the thickness was adjusted according to a pivotal report [8], the prevalence of FH in the present study was still higher than that evaluated on physical examination in other studies [23,24]. Fourth, we did not collect the data regarding the details of statin, including the type, intensity and treatment duration. The differences in these factors might affect the results. Finally, we could not identify the FH-specific plaque component with statistical significance. Although the reason is unclear, we might miss the FH-specific plaque features caused by the limited performance of OCT. Thus, further studies using other intravascular modalities are still required to clarify the FH-specific plaque characteristics.

5. Conclusions

Patients with FH had shorter culprit plaque without significant difference in the prevalence of vulnerable plaque components compared with patients without FH. A higher LDL-C level was associated with higher prevalence of vulnerable plaque in patients with FH. The results of our study further highlight the importance of intensive lipid-lowering therapy for patients with FH, particularly in patients with high LDL-C levels.

Funding sources

None.
Declaration of competing interest

None.

Acknowledgments

We thank Kazuhiro Fujiyoshi, Teruyoshi Nemoto, Ryota Kakizaki, Toshimitsu Sato, Yusuke Muramatsu, Aritomo Katsura, Ayami Kato, and Kiyoshi Asakura for their sincere contribution to the data collection.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.j.plabm.2021.e00202.

References

[1] S.S. Gidding, M.A. Champagne, S.D. De Ferranti, J. Defesche, M.K. Ito, J.W. Knowles, et al., The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association, Circulation 132 (2015) 2167–2192, https://doi.org/10.1161/CIR.0000000000000297.

[2] M. Harada-Shiba, J. Ako, H. Ari, A. Hirohata, Y. Murakami, A. Nohara, et al., Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome in Japan: results of the EXPLORE-J study, Atherosclerosis 277 (2018) 362–368, https://doi.org/10.1016/j.atherosclerosis.2018.06.056.

[3] J. Pang, A. Abraham, C. Vargas-Garcia, T.B. Bates, D.C. Chan, A.J. Hooper, et al., An age-matched computed tomography angiographic study of coronary atherosclerotic plaques in patients with familial hypercholesterolaemia, Atherosclerosis 298 (2020) 52–57, https://doi.org/10.1016/j.atherosclerosis.2020.03.001.

[4] D.D. Sugrue, G.R. Thompson, C.M. Oakley, I.M. Trayner, R.E. Steiner, Contrasting patterns of coronary atherosclerosis in normcholesterolaemic smokers and patients with familial hypercholesterolemia, Br. Med. J. 283 (1981) 1358–1360, https://doi.org/10.1136/bmj.283.6303.1358.

[5] Z. Liu, J. Peng, S. Wang, T. Jiang, C. Zhang, et al., Percutaneous coronary intervention for a Chinese familial hypercholesterolemic homozygous under the guidance of optical coherence tomography, Atherosclerosis Suppl. 36 (2019) 19–23, https://doi.org/10.1016/j.atherosclerosisup.2019.01.004.

[6] T. Hashimoto, Y. Minami, R. Kakizaki, T. Nemoto, K. Fujiyoshi, K. Meguro, et al., Achilles tendon thickness is associated with disease severity and plaque vulnerability in patients with coronary artery disease, J. Lipidol. 13 (2019) 194–200, https://doi.org/10.1016/j.jlac.2018.10.007.

[7] H. Mabuchi, S. Ito, T. Haba, K. Ueda, R. Ueda, Discrimination of familial hypercholesterolemia and secondary hypercholesterolemia by Achilles’ tendon thickness, Atherosclerosis 28 (1977) 61–68.

[8] M. Nakamura, K. Uno, A. Nakamura, J. Ako, A. Nohara, H. Ari, et al., EXPLORE-J (exploration into the lipid management and persistent risk in patients hospitalized for acute coronary syndrome in Japan): baseline data, the 81st annual scientific meeting of the Japanese circulation society, Late Breaking Cohort Studies (2017 Mar 19), 5–5.

[9] L.K. Jang, G.J. Tearney, B. MacNeill, M. Takano, F. Moselewski, N. Iftima, et al., In vivo characterization of coronary atherosclerotic plaque by use of optical coherence tomography, Circulation 111 (2005) 1551–1555, https://doi.org/10.1161/01.CIR.0000159354.43778.69.

[10] G.J. Tearney, E. Regar, T. Akasaka, T. Adriaenssens, P. Barlis, H.G. Bezerra, et al., Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation, J. Am. Coll. Cardiol. 59 (2012) 1568–1572, https://doi.org/10.1016/j.jacc.2011.09.079.

[11] H. Kitabata, A. Tanaka, T. Kubo, S. Takarada, M. Kashiwagi, H. Tsuchioka, et al., Relation of microchannel structure identified by optical coherence tomography to plaque vulnerability in patients with coronary artery disease, Am. J. Cardiol. 105 (2010) 1673–1678, https://doi.org/10.1016/j.amjcard.2010.01.346.

[12] L. Liu, J.A. Gardecki, S.K. Nadkarni, J.D. Tourssaint, Y. Yagi, B.E. Bouma, et al., Imaging the subcellular structure of human coronary atherosclerosis using micro-optical coherence tomography, Nat. Med. 17 (2011) 1010–1014, https://doi.org/10.1038/nm.2409.

[13] D.S. Ong, J.S. Lee, T. Soeda, T. Higuma, Y. Minami, R. Kakizaki, et al., Coronary calcification and plaque vulnerability: an optical coherence tomographic study, Circ. Cardiovasc. Imag. 9 (2016) 1–8, https://doi.org/10.1161/CIRCIMAGING.115.003929.

[14] S. Ehara, Y. Kobayashi, M. Yoshiyama, K. Shimada, Y. Shimada, D. Fukuda, et al., Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study, Circulation 110 (2004) 3424–3429, https://doi.org/10.1161/01.CIR.0000148131.41425.E9.

[15] D. Matsumoto, J. Shite, T. Shinke, H. Otake, Y. Tanino, D. Ogasawara, et al., T. Neointimal coverage of sirolimus-eluting stents at 6-month follow-up: evaluated by optical coherence tomography, Eur. Heart J. 28 (2007) 961–967, https://doi.org/10.1093/eurheartj/ehl413.

[16] P. Libby, Collagenases and cracks in the plaque, J. Clin. Invest. 123 (2013) 3201–3203, https://doi.org/10.1172/JCI67526.

[17] I. Tabas, K.E. Bornfeldt, Macrophage phenotype and function in different stages of atherosclerosis, Circ. Res. 118 (2016) 653–667, https://doi.org/10.1161/CIRCRESAHA.115.306256.

[18] S. Tahara, T. Morooka, Z. Wang, H.G. Bezerra, A.M. Rollins, D.I. Simon, et al., Intravascular optical coherence tomography detection of atherosclerosis and inflammation in Murine aorta, Arterioscler. Thromb. Vasc. Biol. 32 (2012) 1150–1157, https://doi.org/10.1161/ATVBAHA.111.246326.

[19] P.R.S. Silva, C.E. James, J.D.C. Marsiglia, J.E. Krieger, R.D. Santos, A.C. Pereira, Predictors of cardiovascular events after one year of molecular screening for Familial hypercholesterolemia, Atherosclerosis 250 (2016) 144–150, https://doi.org/10.1016/j.atherosclerosis.2016.05.023.

[20] A. V Khera, H. Won, G.M. Peloso, K.S. Lawson, T.M. Bartz, X. Deng, et al., Diagnostic yield of sequencing familial hypercholesterolemia genes in severe hypercholesterolemia, J. Am. Coll. Cardiol. 67 (2016) 2578–2589, https://doi.org/10.1016/j.jacc.2016.03.520.Diagnostic.

[21] L.A. Neefjes, G.J.R. ten Kate, R. Alexia, K. Nieman, A.J. Galemia-Boers, J.G. Langendonk, et al., Accelerated subclinical coronary atherosclerosis in patients with familial hypercholesterolemia, Atherosclerosis 219 (2011) 721–727, https://doi.org/10.1016/j.atherosclerosis.2011.09.052.
[22] J. Tian, X. Ren, R. Vergallo, L. Xing, H. Yu, H. Jia, et al., Distinct morphological features of ruptured culprit plaque for acute coronary events compared to those with silent rupture and thin-cap fibroatheroma: a combined optical coherence tomography and intravascular ultrasound study, J. Am. Coll. Cardiol. 63 (2014) 2209–2216, https://doi.org/10.1016/j.jacc.2014.01.061.

[23] P. Faggiano, A. Pirillo, R. Griffo, M. Ambrosetti, R. Pedretti, G. Scorcu, et al., Prevalence and management of familial hypercholesterolemia in patients with coronary artery disease: the heredity survey, Int. J. Cardiol. 252 (2018) 193–198, https://doi.org/10.1016/j.ijcard.2017.10.105.

[24] P. Hu, K.I. Dharmayat, C.A.T. Stevens, M.T.A. Sharabiani, R.S. Jones, G.F. Watts, et al., Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis, Circulation 141 (2020) 1742–1759, https://doi.org/10.1161/CIRCULATIONAHA.119.044795.